Germany's Lanxess to buy U.S. chemical firm Chemtura for $2.7 billion
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
A logo of Lanxess is seen next to dark clouds at Cologne Bonn airport March 27, 2015. REUTERS/Wolfgang Rattay
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
By Ludwig Burger
FRANKFURT (Reuters) - Lanxess AG
Lanxess's offer of $33.50 per share is a premium of about 19 percent to the Philadelphia-based company's share-price close on Friday.
The world's largest synthetic rubber maker will use existing funds and new debt to buy Chemtura, Lanxess said in a statement, describing the deal as its largest ever acquisition.
It is part of its push to diversify away from the synthetic rubber unit, which depends heavily on the car industry and is under pressure from rivals. It agreed to sell a 50 percent stake in that business to Saudi Aramco for 1.2 billion euros last year.
Its new core business includes highly specialized substances such as ingredients for drugs and pesticides, leather-tanning chemicals, construction pigments for concrete and roofing tiles, and water treatment chemicals.
The Chemtura deal will help it boost its industrial lubricant additives and flame retardant additives businesses.
It follows the 2010 takeover of Dutch company DSM for around 310 million euros and Brazilian rubber producer Petroflex in 2008 for 280 million euros.
The shares rose 8 percent to their highest in more than a year on Monday, and were the best performers on the European STOXX 600 index <.STOXX>.
UBS analyst Patrick Rafaisz said the price represented a multiple of 10 over earnings before interest, taxes, depreciation and amortization (EBITDA) and just seven times when including targeted synergies.
"The price paid for expanding is reasonable, in our view, and a refreshing discount to the early- to mid teens multiples that have become more typical in M&A during the last few quarters," Rafaisz said.
The boards of both companies have unanimously approved the deal, which is expected to close around mid-2017, Chemtura said in a separate statement.
Lanxess also said it will no longer pursue its earlier-announced share buy back of around 200 million euros.
Morgan Stanley advised Chemtura on the deal.
(Additional reporting by Ismail Shakil in Bengaluru; Editing by Tina Bellon and Susan Thomas)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA/Merrill Lynch Upgrades CF Industries (CF) to Buy, Says "Consensus Estimates Now Beatable"
- DryShips (DRYS) Acquires Its First VLGC With 5 Year Time Charter Attached to Oil Major
- Rite Aid (RAD)/Walgreens (WBA) Antitrust Concerns Doesn't Mean Deal is Dead, Says Deutsche Bank
Create E-mail Alert Related CategoriesReuters
Related EntitiesUBS, Morgan Stanley, Earnings, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!